Skip to main content
Erschienen in: Tumor Biology 6/2016

28.12.2015 | Original Article

The clinicopathologic differences of central lymph node metastasis in predicting lateral lymph node metastasis and prognosis in papillary thyroid cancer associated with or without Hashimoto’s thyroiditis

verfasst von: Youzhi Zhu, Ke Zheng, Huihao Zhang, Ling Chen, Jiajie Xue, Mingji Ding, Kunlin Wu, Zongcai Wang, Lingjun Kong, Xiangjin Chen

Erschienen in: Tumor Biology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

This study aims to evaluate the difference of central lymph node metastases (LNM) in papillary thyroid carcinoma (PTC) associated with or without Hashimoto’s thyroiditis (HT) in predicting lateral node metastasis. A retrospective case control study was performed. Patients (1276) with PTC who underwent a total or near-total thyroidectomy with at least one lymph node dissection in our institution were retrospectively reviewed. All patients were divided into two groups (HT-group and non-HT group) according to the pathological diagnosis. In HT-group, the incidence of both central and lateral LNM was lower compared with non-HT group. The average of central metastatic lymph node radio (LNR) was also lower than that in Non-HT group. The multivariate analysis showed that the number of metastatic central LNs (HT ≥ 4, Non-HT ≥ 2) and the central LNR (HT ≥ 0.4, Non-HT ≥ 0.6) were independently associated with lateral LNM. Patients with HT need larger primary tumor size, more positive central LN and higher LNR to predict the presence of lateral LNM. HT may protect against central and lateral LNM in PTC. The number of positive central LNs and central LNR in PTC could be used to determine the presence of lateral LNM and inform postoperative follow-up.
Literatur
1.
Zurück zum Zitat Hodgson N, Wohler-Torres B, Solarzano C. Thyroid cancer: is the incidence still increasing. Ann Surg Oncol. 2004;11(12):1093–7.CrossRefPubMed Hodgson N, Wohler-Torres B, Solarzano C. Thyroid cancer: is the incidence still increasing. Ann Surg Oncol. 2004;11(12):1093–7.CrossRefPubMed
2.
Zurück zum Zitat Weiping T, Zhongyan S, Xiaochun T, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354(26):2783–93.CrossRef Weiping T, Zhongyan S, Xiaochun T, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354(26):2783–93.CrossRef
3.
Zurück zum Zitat Teng X, Shan Z, Chen Y, et al. More than adequate iodine intake may increase subclinical hypothyroidism and autoimmune thyroiditis: a cross-sectional study based on two Chinese communities with different iodine intake levels. Eur J Endocrinol. 2011;164(6):943–50.CrossRefPubMed Teng X, Shan Z, Chen Y, et al. More than adequate iodine intake may increase subclinical hypothyroidism and autoimmune thyroiditis: a cross-sectional study based on two Chinese communities with different iodine intake levels. Eur J Endocrinol. 2011;164(6):943–50.CrossRefPubMed
4.
Zurück zum Zitat Gul K, Dirikoc A, Kiyak G, et al. The association between thyroid carcinoma and Hashimoto’s thyroiditis: the ultrasonographic and histopathologic characteristics of malignant nodules. Thyroid. 2010;20(4):230–1. Gul K, Dirikoc A, Kiyak G, et al. The association between thyroid carcinoma and Hashimoto’s thyroiditis: the ultrasonographic and histopathologic characteristics of malignant nodules. Thyroid. 2010;20(4):230–1.
5.
Zurück zum Zitat Zhu Y, Chen X, Zhang Z, et al. Clinical and pathological analysis of thyroid carcinoma coexistent with Hashimoto’s thyroiditis. Chin J Clin Oncol. 2012;39(4):217–20. Zhu Y, Chen X, Zhang Z, et al. Clinical and pathological analysis of thyroid carcinoma coexistent with Hashimoto’s thyroiditis. Chin J Clin Oncol. 2012;39(4):217–20.
6.
Zurück zum Zitat Singh B, Shaha AR, Trivedi H, et al. Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999;126:1070–6. discussion 1076–7.CrossRefPubMed Singh B, Shaha AR, Trivedi H, et al. Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999;126:1070–6. discussion 1076–7.CrossRefPubMed
7.
Zurück zum Zitat Kebebew E, Treseler PA, Ituarte PHG, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg. 2001;25(5):632–7.CrossRefPubMed Kebebew E, Treseler PA, Ituarte PHG, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg. 2001;25(5):632–7.CrossRefPubMed
8.
Zurück zum Zitat Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71(10):874–8.PubMed Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71(10):874–8.PubMed
9.
Zurück zum Zitat Lee J H, Kim Y, Choi J W, et al. The association between papillary thyroid carcinoma and histologically-proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol. 2012;168(3). Lee J H, Kim Y, Choi J W, et al. The association between papillary thyroid carcinoma and histologically-proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol. 2012;168(3).
10.
Zurück zum Zitat Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946–54.CrossRefPubMed Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946–54.CrossRefPubMed
11.
Zurück zum Zitat Moo TAS, Umunna B, Kato M, et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg. 2009;250(3):403–8.PubMed Moo TAS, Umunna B, Kato M, et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg. 2009;250(3):403–8.PubMed
12.
Zurück zum Zitat Jong-Lyel R, Jae-Yong P, Il PC. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–10.CrossRef Jong-Lyel R, Jae-Yong P, Il PC. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–10.CrossRef
13.
Zurück zum Zitat Goropoulos A, Karamoshos KA, Ntitsias T, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg. 2006;30(12):140.CrossRef Goropoulos A, Karamoshos KA, Ntitsias T, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg. 2006;30(12):140.CrossRef
14.
Zurück zum Zitat Roh JL, Kim JM, Chan IP. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol. 2008;15(9):2482–6.CrossRefPubMed Roh JL, Kim JM, Chan IP. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol. 2008;15(9):2482–6.CrossRefPubMed
15.
Zurück zum Zitat Knecht H, Saremaslani P, Hedinger C. Immunohistological findings in Hashimoto’s thyroiditis, focal lymphocytic thyroiditis and thyroiditis de Quervain. Comparative study. Virchows Arch A Pathol Anat Histol. 1981;393(2):215–31.CrossRefPubMed Knecht H, Saremaslani P, Hedinger C. Immunohistological findings in Hashimoto’s thyroiditis, focal lymphocytic thyroiditis and thyroiditis de Quervain. Comparative study. Virchows Arch A Pathol Anat Histol. 1981;393(2):215–31.CrossRefPubMed
16.
Zurück zum Zitat Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed
17.
Zurück zum Zitat Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;144(1):228.CrossRef Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;144(1):228.CrossRef
18.
Zurück zum Zitat Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol. 2002;10(2):141–6.CrossRefPubMed Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol. 2002;10(2):141–6.CrossRefPubMed
19.
Zurück zum Zitat Souza SL, Lv MDA, Ward LS. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid. 2003;13(5):491–5.CrossRefPubMed Souza SL, Lv MDA, Ward LS. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid. 2003;13(5):491–5.CrossRefPubMed
20.
Zurück zum Zitat Chistiakov DA. Immunogenetics of Hashimoto’s thyroiditis. J Autoimmune Dis. 2005; 2. Chistiakov DA. Immunogenetics of Hashimoto’s thyroiditis. J Autoimmune Dis. 2005; 2.
21.
Zurück zum Zitat Yip J, Orlov S, Orlov D, et al. Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. Head Neck. 2012;35(4):592–8.CrossRefPubMed Yip J, Orlov S, Orlov D, et al. Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. Head Neck. 2012;35(4):592–8.CrossRefPubMed
22.
Zurück zum Zitat Nunes JHV, Clark JR, Kan G, et al. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma. Thyroid. 2013;23(7):811–6.CrossRef Nunes JHV, Clark JR, Kan G, et al. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma. Thyroid. 2013;23(7):811–6.CrossRef
23.
Zurück zum Zitat Schneider DF, Mazeh H, Chen H, et al. Lymph node ratio predicts recurrence in papillary thyroid cancer. Oncologist. 2013;172(2):236–7. Schneider DF, Mazeh H, Chen H, et al. Lymph node ratio predicts recurrence in papillary thyroid cancer. Oncologist. 2013;172(2):236–7.
24.
Zurück zum Zitat Ryu IS, Chan IS, Choi SH, et al. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol. 2014;21(1):277–83.CrossRefPubMed Ryu IS, Chan IS, Choi SH, et al. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol. 2014;21(1):277–83.CrossRefPubMed
25.
Zurück zum Zitat Soo KS, Joo LB, Choon LJ, et al. Coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck. 2011;33(9):1272–7.CrossRef Soo KS, Joo LB, Choon LJ, et al. Coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck. 2011;33(9):1272–7.CrossRef
26.
Zurück zum Zitat Zeng R, Zhang W, Gao E, et al. Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma. Head Neck. 2014;36(1):101–6.CrossRefPubMed Zeng R, Zhang W, Gao E, et al. Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma. Head Neck. 2014;36(1):101–6.CrossRefPubMed
Metadaten
Titel
The clinicopathologic differences of central lymph node metastasis in predicting lateral lymph node metastasis and prognosis in papillary thyroid cancer associated with or without Hashimoto’s thyroiditis
verfasst von
Youzhi Zhu
Ke Zheng
Huihao Zhang
Ling Chen
Jiajie Xue
Mingji Ding
Kunlin Wu
Zongcai Wang
Lingjun Kong
Xiangjin Chen
Publikationsdatum
28.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4706-2

Weitere Artikel der Ausgabe 6/2016

Tumor Biology 6/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.